Five patients with neuroleptic malignant syndrome (NMS) are described. The syndrome developed earlier and took longer to resolve in patients with schizophrenic disorders. Deterioration in the level of consciousness presented earlier than rigidity and fever in all five patients and was thus considered a major criterion. A significant proportion of the patients showed abnormalities of gaze. In four of the five patients spontaneous recovery occurred without the need for specific drugs.
drugs.
Neuroleptic malignant syndrome (NMS) is an uncommon occasionally fatal response to neuroleptic drugs and is characterised by hyperpyrexia, muscular rigidity, autonomic dysfunction and an altered level of consciousness. ' 2 The syndrome has been described as a result of increasing the dose of neuroleptic drugs within the therapeutic range, rather than as a toxic manifestation. ` 
Cessation of all neuroleptic medication resulted in a gradual but total recovery of the patient within seven days of taking CPZ, promethazine and haloperidol. He was reintroduced to CPZ without adverse effects.
Case 4 A 23 year old male catatonic schizophrenic received haloperidol 20 mg intravenously to control his transient agitated restless state in addition to his daily dose of CPZ. Six hours later he became drowsy, mute and semiconscious. Twenty four hours later he became febrile with rigidity, retention of urine, tachycardia, tachypnoea, excessive sweating and a gaze paresis to the left. All neuroleptic drugs were discontinued. He became afebrile on the fifth day, regained normal muscle tone and bladder control on the tenth day after administration of haloperidol. Subsequent intake of CPZ for his schizophrenic state has been uneventful.
Case 5
This 55 year old female hypertensive schizophrenic was on multiple neuroleptics including butyrophenones. Four days before admission she became febrile, disoriented and lapsed into semiconsciousness. Within 48 hours of admission she became hyperpyrexial, developed a Parkinsonian type rigidity with tremor of all four extremities. All neuroleptic drugs were discontinued. She became afebrile six days after admission. However, her Parkinsonian rigidity and tremor continued. She was given a combination of levodopa and dopadecarboxylase inhibitor in gradually increasing doses as well as bromocryptine. She was able to walk within two weeks of admission and a gradual reduction in the dose of her anti-Parkinsonian drugs was continued at follow up. During her illness she developed renal failure with bacterial septicaemia which regressed completely by the time she was discharged. Blood culture showed a profuse growth of gram negative organism (E Coli). Cultures Various ocular abnormalities have been described as a side effect of phenothiazine and amitryptyline and infrequently as a component of NMS. These include oculogyric crises and internuclear ophthalmoplegias. '3 16'9 However, to our knowledge, gaze paresis seen in two of our patients has not previously been described. Recovery from gaze paresis, with resolution of NMS, makes a structural lesion of the hemispheres or brainstem unlikely. Reversal of amitriptyline induced internuclear ophthalmoplegia by intravenous physostigmine20 suggests that mechanisms other than dopaminergic receptor blockade are also operative in the production of ocular dysfunction in NMS. Urinary incontinence has been described frequently in association with NMS,8 however, we are unable to explain the prolonged periods of urinary retention in three of our patients. Since these patients continued to exhibit this physical sign despite regaining normal conscious levels, lowered levels of consciousness cannot be the explanation.
We can find no suitable explanation for the earlier onset of NMS and its prolonged duration with a greater mortality in patients with schizophrenic disorder2 2122 compared with the affective disorders. Unlike other reported instances of NMS where dantrolene and/or dopamine receptor agonists were used as therapeutic measures, these drugs were not needed except in one case. Neuroleptic malignant syndrome has been reported to have a mortality of 20%.1 All our patients recovered.
Our patients might represent different degrees of response to phenothiazines and butyrophenones. We have no reason to believe that our patients showed a different form of NMS.
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